|
|
| A B C D E F G H I J K L M N O P Q R S T U V W X Y Z # |
HLA-B*5701 Typing
Test Code19774
CPT Codes
81381
Physician Attestation of Informed Consent
This germline genetic test requires physician attestation that patient consent has been received if ordering medical facility is located in AK, DE, FL, GA, IA, MA, MN, NV, NJ, NY, OR, SD or VT or test is performed in MA.
Includes
Additional testing by Sequence Based Typing (SBT) may be performed when necessary.
Preferred Specimen
5 mL whole blood collected in an EDTA (lavender-top) tube
Minimum Volume
3 mL
Other Acceptable Specimens
Whole blood collected in: sodium heparin (green-top) tube, EDTA (pink-top), EDTA (royal blue-top), or sodium citrate (light blue-top) tube
Instructions
A separate EDTA (lavender-top) tube must be submitted for all HLA testing. If submitted with any other test requiring an EDTA tube, please submit a separate tube for this test. Do not open tube.
Transport Temperature
Room temperature
Specimen Stability
Room temperature: 7 days
Refrigerated: 7 days
Frozen: Unacceptable
Refrigerated: 7 days
Frozen: Unacceptable
Reject Criteria (Eg, hemolysis? Lipemia? Thaw/Other?)
Received frozen • Clotted
Methodology
Polymerase Chain Reaction (PCR) • Sequence Specific Oligonucleotide Probes (SSO)
Setup Schedule
Set up: Daily; Report available: 6 days
Limitations
A negative result does not rule out the risk for ABC HSR and clinical vigilance should be maintained regardless of the result. The frequency of HLA/-B5701 is approximately 8% in Caucasians and 2% in African Americans.
Reference Range
See Laboratory Report
Clinical Significance
Abacavir therapy for HIV treatment is associated with significant drug hypersensitivity in approximately 8% of recipients, with retrospective studies indicating a strong association with the HLA-B*5701 Allele. HLA-B*5701 typing can be used for genetic risk stratification prior to initiation of Abacavir therapy.
